Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

3

Revenue 2017

MabThera/Rituxan

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. MabThera/Rituxan was produced by Roche.

NICE backs Roche’s Gazyvaro after initial rejection

NICE backs Roche’s Gazyvaro after initial rejection clinical profile justified premium pricing over Mabthera (rituximab), Roche’s older drug for the FL indication. ... Like MabThera, Gazyvaro targets the CD20 receptor but has been designed with sugar molecule side chains that improve its therapeutic and

Roche faces biosimilar blitz in 2018

Roche faces biosimilar blitz in 2018 Novartis’ unit Sandoz and Celltrion/Mundipharma’s Truxima have also claimed a European approval for its biosimilar versions of Roche’s immunotherapy drug MabThera (rituximab). ... Additionally, Rituxan is expected to plummet by 16% to CHF 6.1bn

Novartis doubles down on biosimilars with Biocon alliance

Novartis doubles down on biosimilars with Biocon alliance In the last couple of years it has picked up approvals for Rixathon - a biosimilar of Roche’s cancer and arthritis drug MabThera (rituximab) - as well as its Erelzi version of

Roche buys cancer company Ignyta for $1.7bn

Roche buys cancer company Ignyta for $1.7bn It has been bolstering its oncology pipeline in particular as three of its top-selling drugs – Avastin, Herceptin and Rituxan – are starting to face biosimilar competition.

Roche's Actemra/RoActemra receives new European approval

Roche's Actemra/RoActemra receives new European approval Horning said: “By challenging our own MabThera medicine head-to-head, we have been able to set a new standard of care for people with follicular lymphoma. ... with follicular lymphoma who did not respond to or who progressed during or up to six months

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...

Infographics